Warner-lambert Company

Haile Tecle

Stephen Douglas Barrett

Walter H Moos

Alexander James Bridges

David A Downs

Annette Marian Doherty

Alan Robert Saltiel

David Thomas Dudley

David J Lauffer

Michael David Kaufman

David W Moreland

Stephen C Bergmeier

Juan C Jaen

Mel C Schroeder

Anthony J Thomas

Joseph Scott Warmus

Donna Reynolds Cody

Helen Tsenwhei Lee

Michael R Pavia

Karen Elaine Sexton

Roy Thomas Winters

Stephen Alan Fakhoury

Jared Bruce John Milbank

Kevin Matthew Schlosser

Jessica Elizabeth Reed

Cathlin Marie Biwersi

Lawrence D Wise

Gordon William Rewcastle

Richard John Booth

Julie Ann Spicer

Thomas Gary Heffner

Leonard Theodore Meltzer

Linda L Coughenour

Robert E Davis

Yazhong Pei

Donald E Butler

Bradley W Caprathe

John H Dodd

Mark Alan Schwindt

Lloyd Charles Franklin

Corinne E Augelli-Szafran

Sheila H Hobbs

Michael Huai Gu Chen

Howard Yoshihisa Ando

Jeffrey A Kester

Steven Edward Rose

Cathlin Marie Flamme

Alistair Dixon

Kevin Lee

Robert Pinnock

Adam A Galan

Kathryn B Sanders

Lu-Yan Zhang

Michael Chen

Cathlin Biwersi

Jared Bruce Milbank

This invention provides quinazoline compounds of the formula: 

4-phenylamino-quinazolin-6-yl-amides

This invention provides quinazoline compounds of the formula: wherein: Ris halo; Ris H or halo; Ris a) C-Calkyl, optionally substituted by halo; or b) &#x2014;(CH)-morpholino, &#x2014;(CH)-piperidine, &#x2014;(CH)-piperazine, &#x2014;(CH)-piperazine-N(C-Calkyl), &#x2014;(CH)-pyrrolidine, or &#x2014;(CH)-imidazole; n is 1 to 4; Ris &#x2014;(CH)-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C-Calkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH, NH(C-Calkyl) or N(C-Calkyl); m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.

This invention provides quinazoline compounds of the formula: wherein: Ris halo; Ris H or halo; Ris a) C-Calkyl, optionally substituted by halo; or b) &#x2014;(CH)-morpholino, &#x2014;(CH)-piperidine, &#x2014;(CH)-piperazine, &#x2014;(CH)&#x2014;-piperazine-N(C-Calkyl), &#x2014;(CH)-pyrrolidine, or &#x2014;(CH)-imidazole; n is 1 to 4; Ris &#x2014;(CH)-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C-Calkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH, NH(C-Calkyl) or N (C-Calkyl); m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.

The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystalline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids

Phenylamino benzhydroxamic acid derivatives of the formula where R, R, R, R, R, and Rare hydrogen or substituent groups such as alkyl, and where Ris hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.

4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors

The present invention relates to N-methyl-substituted benzamidazole derivatives of formula (I): as defined in the specification; pharmaceutical compositions and methods of use thereof.

N-methyl-substituted benzamidazoles

The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

N-(4 substituted phenyl)-anthranilic acid hydroxamate esters

The invention features a method for treating chronic pain using a compound of formula (I).

Method for treating chronic pain using MEK inhibitors

Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula

2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives

Diarylamines, such as 5-amide substituted diarylamines of formula (I) or formula (II) wherein A is hydroxy, Calkoxy, or NROR; X is OR, NRR, or NR; inhibitors of MEK and are useful in the treatment of a variety of proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.

Substituted diarylamines as MEK inhibitors

The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids

N-(4-substituted phenyl)-anthranilic acid hydroxamate esters

Sulfohydroxamic acid diarylamines and derivatives thereof; compositions made from them; and methods of using them.

Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors

Phenylamino benzhydroxamic acid derivatives of formula (I) where R , R , R , R , R , and R are hydrogen or substituent groups such as alkyl, and where R is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.

4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors

Benzenesulfonamide derivatives and their use as MEK inhibitors

Growing community of inventors

Ann Arbor, MI, United States of America

Haile Tecle